Merck's Keytruda succeeds in key lung cancer trial
Merck & Co Inc's blockbuster drug Keytruda in combination with two chemotherapy drugs was successful as a first line treatment for lung cancer, results from a key late-stage study showed on Tuesday. The results present a challenge to Swiss drugmaker Roche and Merck's U.S. rival Bristol-Myers Squibb Co, both of which are developing key lung cancer combination treatments of their own.
from Biotech News
0 Comments